ISS (Reference)
Friday, September 8, 6:00 p.m. - 8:30 p.m.
ASH appreciates its corporate and nonprofit partners for their participation in Independent Satellite Symposia. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs.
ASH appreciates its corporate and nonprofit partners for their participation in Independent Satellite Symposia. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs.
This program is provided by MediCom Worldwide, Inc. and supported by educational grants from Amgen, Inc. and Celgene Corporation.
Location: Gold Room
Program Chair
Robert Z. Orlowski, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX
Speakers
- Ajay K Nooka, MD, MPH, Winship Cancer Institute, Emory University, Atlanta, GA
- Peter M. Voorhees, MD, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC
Relapsed/refractory multiple myeloma (RRMM) is one of the most challenging hematologic malignancies that oncology practitioners will treat. Often, patients with RRMM have significant comorbidities and multiple prior treatment failures, all of which complicate both therapeutic decisions and subsequent patient management.
In this focused symposium, a panel of internationally known experts in myeloma will utilize an interactive approach to discuss new and emerging therapeutic strategies for RRMM. Following a robust analysis of evolving treatments and clinical trial data, participants will be challenged to identify the most appropriate and effective treatment for a series of case studies of complex RRMM patients. Through discussion and analysis, symposium attendees will gain a greater understanding of how to effectively address the real-world challenges of disease progression, comorbid conditions, high-risk factors, and treatment-emergent adverse events in their patients with RRMM.
- Individualizing Treatment for Your Patients with Relapsed/Refractory Multiple Myeloma: Selecting Among the Available Options
- Optimal Strategies for the Identification and Management of Treatment-Related Adverse Events
- Adapting Treatment Strategies: A Series of Interactive Guided Case Studies
- Ask the Expert: Bring Your Most Challenging Case for Discussion
- Improving Practice and Future Perspectives: Clinical Pearls Panel Discussion and Questions from the Audience
Contact
Lisa Hanes
MediCom Worldwide
[email protected]
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission